Srikumar Sahasranaman

1.6k total citations
42 papers, 1.2k citations indexed

About

Srikumar Sahasranaman is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Srikumar Sahasranaman has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Srikumar Sahasranaman's work include Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Srikumar Sahasranaman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Srikumar Sahasranaman collaborates with scholars based in United States, China and France. Srikumar Sahasranaman's co-authors include Sandip Kumar Roy, Danny R. Howard, Manish Gupta, Günther Hochhaus, Nageshwar Budha, Ying Ou, Anand Rotte, Zhiyu Tang, John Catalano and Halyna Pylypenko and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Srikumar Sahasranaman

41 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Srikumar Sahasranaman United States 18 379 359 202 193 164 42 1.2k
Feng Luo United States 22 496 1.3× 552 1.5× 129 0.6× 119 0.6× 142 0.9× 36 1.3k
Maria Palmisano United States 23 503 1.3× 385 1.1× 135 0.7× 174 0.9× 150 0.9× 85 1.5k
Ihor Batruch Canada 28 926 2.4× 256 0.7× 94 0.5× 178 0.9× 207 1.3× 55 1.9k
Aru Narendran Canada 25 908 2.4× 516 1.4× 168 0.8× 195 1.0× 149 0.9× 115 1.7k
Ken Ohmine Japan 21 605 1.6× 528 1.5× 210 1.0× 119 0.6× 73 0.4× 82 1.4k
Brent D. G. Page Canada 21 723 1.9× 758 2.1× 88 0.4× 238 1.2× 77 0.5× 52 1.6k
Sukyung Woo United States 25 1.0k 2.8× 460 1.3× 112 0.6× 252 1.3× 377 2.3× 63 2.2k
Chien-Shing Chen United States 24 1.1k 2.9× 389 1.1× 100 0.5× 251 1.3× 173 1.1× 60 2.0k
Xiaochun Wang China 24 730 1.9× 411 1.1× 129 0.6× 168 0.9× 242 1.5× 64 1.7k
Matthew J. Taylor United States 21 646 1.7× 237 0.7× 155 0.8× 117 0.6× 107 0.7× 33 1.8k

Countries citing papers authored by Srikumar Sahasranaman

Since Specialization
Citations

This map shows the geographic impact of Srikumar Sahasranaman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srikumar Sahasranaman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srikumar Sahasranaman more than expected).

Fields of papers citing papers by Srikumar Sahasranaman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srikumar Sahasranaman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srikumar Sahasranaman. The network helps show where Srikumar Sahasranaman may publish in the future.

Co-authorship network of co-authors of Srikumar Sahasranaman

This figure shows the co-authorship network connecting the top 25 collaborators of Srikumar Sahasranaman. A scholar is included among the top collaborators of Srikumar Sahasranaman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srikumar Sahasranaman. Srikumar Sahasranaman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sahasranaman, Srikumar, Xianbin Tian, Ying Fei Li, et al.. (2025). Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact. Clinical and Translational Science. 18(5). e70221–e70221. 3 indexed citations
2.
Rizwan, Ahsan, Hugh Giovinazzo, Kun Wang, et al.. (2025). Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach. Clinical and Translational Science. 18(5). e70223–e70223.
3.
Tang, Zhiyu, et al.. (2024). Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors. Clinical and Translational Science. 17(3). e13769–e13769. 3 indexed citations
4.
5.
Budha, Nageshwar, et al.. (2019). Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors. Annals of Oncology. 30. v182–v183. 1 indexed citations
6.
Yoshida, Kenta, Sravanthi Cheeti, Buyun Chen, et al.. (2019). GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study. Drug Metabolism and Disposition. 47(9). 966–973. 28 indexed citations
7.
Liu, Lichuan, Sravanthi Cheeti, Kenta Yoshida, et al.. (2018). Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects. The Journal of Clinical Pharmacology. 58(11). 1427–1435. 29 indexed citations
8.
Cheeti, Sravanthi, Hao Hou, Eric Nelson, et al.. (2018). Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects. Pharmaceutical Research. 35(12). 233–233. 6 indexed citations
9.
Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2016). Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research. 23(10). 2423–2432. 59 indexed citations
10.
11.
Gupta, Manish, et al.. (2015). Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy. The Journal of Clinical Pharmacology. 56(2). 157–169. 110 indexed citations
12.
Kipps, Thomas J., Herbert Eradat, Sebastian Grosicki, et al.. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leukemia & lymphoma. 56(10). 2826–2833. 151 indexed citations
13.
Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2015). Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Cancer Research. 75(15_Supplement). CT139–CT139. 5 indexed citations
14.
15.
Grégoire, Laurent, Nicolas Morin, Bazoumana Ouattara, et al.. (2011). The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism & Related Disorders. 17(4). 270–276. 89 indexed citations
16.
Sahasranaman, Srikumar, Danny R. Howard, & Sandip Kumar Roy. (2008). Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology. 64(8). 753–767. 290 indexed citations
17.
Sahasranaman, Srikumar, et al.. (2006). Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. European Respiratory Journal. 27(3). 511–516. 29 indexed citations
18.
Mortimer, Kevin, Tim Harrison, Kai Wu, et al.. (2006). Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. British Journal of Clinical Pharmacology. 62(4). 412–419. 44 indexed citations
19.
Sahasranaman, Srikumar, et al.. (2005). METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES. Drug Metabolism and Disposition. 34(2). 225–233. 19 indexed citations
20.
Hochhaus, Günther, Srikumar Sahasranaman, Hartmut Derendorf, & H Möllmann. (2002). Intranasal glucocorticoid delivery: competition between local and systemic effects. 12(1). 23–31. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng Luo Breakdown of academic impact, for papers by Maria Palmisano Breakdown of academic impact, for papers by Ihor Batruch Breakdown of academic impact, for papers by Aru Narendran Breakdown of academic impact, for papers by Ken Ohmine Breakdown of academic impact, for papers by Brent D. G. Page Breakdown of academic impact, for papers by Sukyung Woo Breakdown of academic impact, for papers by Chien-Shing Chen Breakdown of academic impact, for papers by Xiaochun Wang Breakdown of academic impact, for papers by Matthew J. Taylor
Rankless by CCL
2026